The United Laboratories International Holdings (HK:3933) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The United Laboratories International Holdings Limited has announced the acceptance of their Insulin Degludec Injection by China National Medical Products Administration, marking a significant stride in diabetes treatment with their new generation long-acting basal insulin analog. The company is further developing a range of diabetes-related products, emphasizing its commitment to innovation and value creation in the biopharmaceutical industry for its shareholders.
For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue